Please ensure Javascript is enabled for purposes of website accessibility

3 Great Stocks to Buy If You Get a Second Stimulus Check

By Keith Speights - May 19, 2020 at 7:02AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Uncle Sam could be sending more money your way in the not-too-distant future. Buying these stocks will put the extra cash to good use.

Some Americans are still waiting on their stimulus checks from the CARES Act. But that's not stopping representatives in Washington, D.C., from pushing for another wave of economic stimulus. The U.S. House of Representatives passed a new stimulus bill late last week. Although the legislation is likely to die in the U.S. Senate, the White House has reportedly signaled its willingness to move forward with more stimulus spending to help Americans. 

It could be just a matter of time before more money makes its way into the pockets of Americans. Here are three great stocks to buy if you get a second stimulus check.

Paper the size of a check with U.S. Treasury economic stimulus bill printed on it

Image source: Getty Images.

1. Brookfield Renewable Partners

The long-term prospects for renewal energy sources like hydro, solar, and wind are excellent. Brookfield Renewable Partners (BEP -0.32%) ranks as one of the best renewable energy stocks on the market.

One of the first things that investors look at with Brookfield Renewable is its dividend. And for good reason. Its dividend yield stands at a mouthwatering 4.5%. The company's dividend is also arguably one of the safest dividends in the entire energy sector since most of Brookfield Renewable's revenue comes from long-term contracts.

But don't overlook Brookfield Renewable's growth opportunities. Wind and solar are already attractive sources of electric power with their low costs. Countries across the world, as well as large states in the U.S., are behind on their goals of converting to clean energy sources. 

Brookfield Renewable plans to invest up to $800 million in 2020 on development projects and acquisitions to boost its energy production. I expect the company will continue to add capacity over the next several years. The combination of Brookfield Renewable's solid growth prospects and its terrific dividend make this stock a top pick.

2. Mastercard

Sure, Mastercard (MA 0.44%) has taken a hit with the ongoing COVID-19 pandemic. The payment processing giant's profit dropped 9% year over year in the first quarter of 2020 while revenue growth slowed to only 3%. But the headwinds from the coronavirus outbreak will only be temporary.

The pandemic could even boost Mastercard's prospects over the long run by further accelerating the expansion of e-commerce. More consumers have shopped online while they've been stuck at home. And they haven't used cash or checks to make purchases. They've either used credit cards or digital payment methods, many of which rely on Mastercard's huge payment processing network.

It's not just individual consumers who are shifting away from using cash and checks, though. Mastercard recently launched a business-to-business platform called Track that enables businesses and their suppliers to use multiple electronic payment methods in their commercial activities.

The future is a world with significantly lower use of cash and much higher use of digital payments. I think that Mastercard will be a big winner in this future world.

3. Vertex Pharmaceuticals

Some investors are leery of buying biotech stocks. But Vertex Pharmaceuticals (VRTX 0.75%) isn't the super-risky kind of biotech stock that comes to mind for a lot of people.

Vertex enjoys a virtual monopoly in treating the underlying cause of rare genetic disease cystic fibrosis (CF). Its newest CF drug, Trikafta, is off to a fantastic start in the U.S. and is likely to soon win European approval. Vertex expects the addition of Trikafta to its lineup of three other CF drugs will enable it to expand its addressable patient population by more than 50%.

Meanwhile, the company is working hard to move beyond CF. Vertex's pipeline includes promising phase 2 programs targeting pain and another rare genetic disease, alpha-1 antitrypsin deficiency (AATD). The gene-editing therapy that Vertex and partner CRISPR Therapeutics are evaluating in phase 1/2 studies for treating (and potentially curing) rare blood diseases beta-thalassemia and sickle cell disease could be an even bigger game-changer.

The company's success in CF has made it highly profitable and enabled Vertex to amass a big cash stockpile of $4.2 billion as of March 31, 2020. Vertex completed a key acquisition last year, buying Semma Therapeutics for $950 million to get its gene-editing therapy that could potentially cure type 1 diabetes. Look for the biotech to make more acquisitions in the future to fuel even greater growth.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Mastercard Incorporated Stock Quote
Mastercard Incorporated
$320.17 (0.44%) $1.40
Vertex Pharmaceuticals Incorporated Stock Quote
Vertex Pharmaceuticals Incorporated
$291.16 (0.75%) $2.18
Brookfield Renewable Partners L.P. Stock Quote
Brookfield Renewable Partners L.P.
$34.65 (-0.32%) $0.11
CRISPR Therapeutics Stock Quote
CRISPR Therapeutics
$72.70 (2.98%) $2.10

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/07/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.